Cencora
COR
$308.78
-0.20%
Cencora, Inc. is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail pharmacy chains, independent pharmacies, mail-order operators, hospital networks, and healthcare providers, while also operating commercialization services, global specialty logistics through World Courier, European distribution via Alliance Healthcare, and animal health distribution through MWI. Alongside McKesson and Cardinal Health, Cencora controls over 90% of the U.S. pharmaceutical wholesale market, giving it a scale-driven, high-volume, low-margin oligopoly position that is difficult to disrupt. The current investor narrative centers on the company's raised fiscal 2026 EPS outlook and the strengthening of its specialty businesses, which are viewed as higher-margin growth engines that can offset persistent gross-margin pressure in core distribution. At the same time, the stock has lagged the broader market over the past year, and investors are debating whether the specialty-driven earnings momentum can translate into sustained multiple expansion or whether structural margin compression and a leveraged balance sheet will keep the shares range-bound.…
COR
Cencora
$308.78
Related headlines
Investment Opinion: Should I buy COR Today?
Rating: Buy. The core thesis is that Cencora's specialty-driven margin expansion (gross margin up to 4.24% in Q2 2026 from 3.11% in Q4 2025) is underappreciated by a market that has punished the stock for its low-beta, low-growth profile, creating a value opportunity with 19.6% upside to the analyst average target of $369.31. The unanimous buy consensus (13 analysts, mean 1.73) and the fact that even the lowest target of $330.00 is above the current price reinforce the favorable risk/reward.
Supporting evidence includes: (1) forward PE of 15.59x versus trailing PE of 38.97x, implying a dramatic earnings recovery that consensus EPS of $31.74 already reflects; (2) Q2 2026 EBITDA of $2.50 billion on a 3.19% margin, up from $1.04 billion and 1.21% in Q1 2026; (3) TTM free cash flow of $1.56 billion and a sustainable 28.1% dividend payout ratio; and (4) PS ratio of 0.19x and EV/Sales of 0.213x, both near the low end of historical ranges, suggesting the market is pricing in permanent margin deterioration that the specialty mix shift may disprove. The PEG ratio of 7.05 is a concern, but it reflects trailing growth distortions rather than forward earnings power.
The biggest risks that could invalidate the thesis are: (1) a reversal in specialty margins if drug-price inflation normalizes or competitive pressure intensifies; (2) revenue growth decelerating below 3%, which would pressure the forward PE multiple; and (3) balance-sheet stress from 7.13x debt-to-equity and a 0.90 current ratio if credit conditions tighten. The rating would upgrade to a stronger Buy if gross margins hold above 4.5% for two consecutive quarters, and would downgrade to Hold if revenue growth falls below 2% or if free cash flow turns negative for a full fiscal year. Relative to its own history (PS range 0.42x-0.78x) and peers, COR appears undervalued on sales-based metrics but fairly valued on EV/EBITDA of 17.91x.
Sign up to view all
COR 12-Month Price Forecast
Cencora presents a favorable risk/reward for value-oriented investors willing to look through near-term revenue deceleration and balance-sheet leverage. The specialty-driven margin expansion is real and measurable, and the forward PE of 15.59x is undemanding for a business with 90%+ market share in a defensible oligopoly. The main risk is that revenue growth continues to slow and the market refuses to award a higher multiple, keeping the stock range-bound. I would upgrade to high confidence if gross margins hold above 4.5% for two consecutive quarters and revenue growth reaccelerates above 5%; I would downgrade to neutral if revenue growth falls below 2% or if free cash flow turns negative for a full fiscal year.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $369.31 and implied upside of +19.6% versus the current price.
Average Target
$369.31
0 analysts
Implied Upside
+19.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$330 - $430
Analyst target range
Cencora is covered by 13 analysts with a consensus recommendation of "buy" (recommendation mean of 1.73, where 1.0 is a strong buy), and the average price target of $369.31 implies roughly 19.6% upside from the current price of $308.78. The consensus leans bullish, with the institutional ratings history showing a steady stream of Overweight, Outperform, and Buy ratings from Barclays, Wells Fargo, Baird, UBS, Citigroup, Evercore ISI, and JP Morgan through 2026, and no downgrades in the visible record. The estimated EPS average of $31.74 for the forward period, with a tight range of $31.00 to $32.19, suggests analysts have high confidence in the earnings recovery story.
The full target range spans $330.00 to $430.00, a spread of about 30% of the current price, which signals meaningful but not extreme uncertainty. The high target of $430.00 implies roughly 39% upside and likely assumes successful specialty-business scaling, multiple expansion toward the higher end of the distributor range, and continued EPS beats; the low target of $330.00 still implies about 6.9% upside and appears to price in modest growth with stable margins. The fact that even the lowest analyst target is above the current price is a strong bullish signal, and the tight clustering of EPS estimates ($31.00-$32.19) contrasts with the wider price-target spread, suggesting the debate is about the multiple, not the earnings. With 13 analysts and a buy consensus, coverage is adequate for a large-cap name, and the absence of recent downgrades supports the view that the sell-side sees the recent pullback as a buying opportunity rather than the start of a fundamental deterioration.
Bulls vs Bears: COR Investment Factors
The bull case currently has stronger evidence, anchored by a unanimous buy consensus from 13 analysts, a 19.6% average target upside, and tangible margin expansion from the specialty mix shift (gross margin up to 4.24% from 3.11% in Q4 2025). However, the bear case is not without merit: revenue growth has decelerated to 3.85%, the balance sheet carries 7.13x debt-to-equity, and the stock has lagged the S&P 500 by over 20 percentage points year-to-date. The single most important tension is whether the specialty-driven margin improvement can be sustained and scaled enough to offset structural gross-margin pressure in core distribution, or whether it proves to be a temporary mix benefit that fades as drug-price inflation normalizes. If specialty margins hold, the forward PE of 15.59x looks too cheap; if they revert, the stock could remain range-bound or retest the 52-week low.
Bullish
- Analyst consensus buy with 19.6% upside: 13 analysts rate COR a buy (mean 1.73) with an average target of $369.31, implying 19.6% upside from $308.78. Even the lowest target of $330.00 sits 6.9% above the current price, signaling that the sell-side sees the recent pullback as a buying opportunity rather than a fundamental breakdown.
- Specialty mix drives margin expansion: Gross margin rose to 4.24% in Q2 2026 from 3.27% in Q1 2026 and 3.11% in Q4 2025, while EBITDA margin jumped to 3.19% from 1.21% sequentially. The mix shift toward higher-margin specialty and services businesses is having a measurable positive impact on profitability.
- Forward PE of 15.6x is undemanding: The forward PE of 15.59x is near the low end of the 15-20x range typical for large-cap distributors and sits well below the trailing PE of 38.97x, which is distorted by one-time items. With consensus FY2026 EPS of $31.74, the market is pricing in a dramatic earnings recovery that the company is already delivering.
- Oligopoly with 90%+ market share: Cencora, McKesson, and Cardinal Health control over 90% of the U.S. pharmaceutical wholesale market, creating a scale-driven, high-barrier oligopoly. This structure supports stable long-term cash generation, evidenced by TTM free cash flow of $1.56 billion and a sustainable 28.1% dividend payout ratio.
Bearish
- Revenue growth decelerating to 3.85% YoY: Q2 2026 revenue of $78.36 billion grew just 3.85% year-over-year, a sharp slowdown from the double-digit comparisons implied by earlier periods. For a distributor with razor-thin 2.09% net margins, this deceleration limits operating leverage and makes it harder to justify multiple expansion.
- Extreme leverage with 7.13x debt-to-equity: Debt-to-equity stands at 7.13x and the current ratio is 0.90, meaning current liabilities exceed current assets. The working-capital-intensive model produced negative FCF of -$2.42 billion in Q1 2026, and interest coverage of 8.7x leaves limited cushion if margins compress further.
- Persistent relative underperformance vs. SPY: COR has underperformed the S&P 500 by 22.99% over six months and 20.58% year-to-date, even as SPY gained 15.01% over the past year. The 1-month relative strength of -1.66% confirms the stock continues to lag, and the September 3 high of $337.22 has rolled over into a lower-high pattern.
- PEG ratio of 7.05 signals growth mismatch: The PEG ratio of 7.05 is elevated, indicating the stock is not cheap relative to its expected growth rate. With revenue growth at just 3.85% and net margin at 2.09%, the market may be overpaying for a business that is structurally low-growth and low-margin.
COR Technical Analysis
Cencora is in a choppy, range-bound consolidation rather than a clean trend, with the shares up 6.17% over the past year but down 8.88% year-to-date, a divergence that signals a market that has lost momentum after an earlier advance. At a current price of $308.78, the stock sits at roughly 51% of its 52-week range of $244.82 to $377.54, placing it squarely in the middle of the band and suggesting neither an oversold value opportunity nor an overextended momentum name. The 52-week high of $377.54 remains about 22% above the current price, while the 52-week low of $244.82 is roughly 21% below, confirming a balanced, two-sided technical setup.
Recent momentum has been mildly negative and is diverging from the longer-term trend: the stock is down 2.62% over the past month and down 5.55% over six months, even though it is up 13.59% over three months and up 6.17% over a year. This pattern of a strong three-month bounce fading into a weaker one-month print suggests the July-to-September rally is losing steam rather than accelerating, and the 1-month relative strength of -1.66% versus SPY confirms the stock is underperforming the market over the near term. The 6-month relative strength of -22.99% and YTD relative strength of -20.58% are far more damaging, indicating that Cencora has been a persistent laggard even as the S&P 500 gained 15.01% over the past year, and the recent price action from the September 3 high of $337.22 down to $308.78 looks like a lower-high rollover within the range.
Key technical support sits at the 52-week low of $244.82, with the May 6 gap-down low near $252.74 acting as the first major shelf; a breakdown below that zone would signal a resumption of the downtrend and likely target the low $240s. Resistance is defined by the 52-week high of $377.54, with the recent swing high at $337.22 serving as the nearer ceiling; a decisive breakout above $337 would put the stock back in play for a retest of the highs, while failure there reinforces the range. With a beta of just 0.574, Cencora is roughly 43% less volatile than the market, which is defensive for position sizing but also means it will likely lag in strong risk-on rallies; the max drawdown of -32.56% shows that even low-beta names can suffer sharp declines when sentiment turns.
Beta
0.57
0.57x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
+6.2%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | -0.5% |
| 3m | +13.6% | +2.3% |
| 6m | -5.5% | +16.6% |
| 1y | +6.2% | +14.8% |
| ytd | -8.9% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Cencora's revenue trajectory remains solidly growing but is decelerating from the elevated levels of prior periods: fiscal Q2 2026 (quarter ended March 31, 2026) revenue came in at $78.36 billion, up 3.85% year-over-year, a marked slowdown from the double-digit comparisons implied by earlier quarters such as the $85.93 billion reported in Q1 2026 and the $83.73 billion in Q4 2025. The sequential decline from Q1 to Q2 reflects normal seasonality and the absence of large COVID-related or specialty boluses, but the 3.85% YoY growth rate is modest for a distributor and suggests the core business is maturing. Segment data shows Animal Health contributing $1.44 billion and Other Segments $619.8 million, but these are small relative to the core pharmaceutical distribution book, meaning overall growth is still hostage to drug-price inflation and specialty volume trends rather than any single high-growth vertical.
Profitability is razor-thin but improving at the operating line: Q2 2026 net income was $1.64 billion on $78.36 billion of revenue, a net margin of just 2.09%, while gross margin was 4.24% and operating margin 1.72%. The gross margin of 4.24% in Q2 2026 compares favorably to the 3.27% reported in Q1 2026 and the 3.11% in Q4 2025, indicating that the mix shift toward specialty and higher-margin services is having a real, if modest, positive effect. The company swung from a Q4 2025 net loss of $339.7 million (driven by a $1.04 billion negative other-income swing) to a $1.64 billion profit in Q2 2026, and the Q2 2026 EBITDA of $2.50 billion on a 3.19% EBITDA margin is a clear step up from the $1.04 billion and 1.21% margin in Q1 2026, showing that the earnings base is recovering after a volatile stretch.
The balance sheet is the key risk: debt-to-equity stands at 7.13x, the current ratio is 0.90 (below 1.0, indicating current liabilities exceed current assets), and the company carries a massive working-capital-intensive distribution model. Free cash flow is lumpy and often negative in the first half of the fiscal year, with Q1 2026 FCF of -$2.42 billion and Q2 2026 FCF of $1.17 billion, though the trailing-twelve-month FCF of $1.56 billion and a TTM FCF per share of $6.03 show the business does generate cash over a full cycle. ROE of 103.06% looks spectacular but is an artifact of a very small equity base (equity multiplier of 24.0x), not a sign of capital efficiency; the more meaningful ROA of 3.56% and interest coverage of 8.7x indicate that the company services its debt comfortably but has limited cushion if margins compress further.
Quarterly Revenue
$78.4B
2026-03
Revenue YoY Growth
+3.9%
YoY Comparison
Gross Margin
4.2%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Because Cencora is profitable (Q2 2026 net income of $1.64 billion), the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 38.97x versus a forward PE of 15.59x. The enormous gap between trailing and forward multiples implies the market expects a dramatic earnings recovery, with consensus FY2026 EPS estimates of $31.74 versus the trailing EPS of $0.0257, a figure that reflects the distortion from the Q4 2025 loss and other one-time items rather than the true earnings power. On a forward basis, 15.59x is a reasonable multiple for a low-margin distributor, but the trailing figure is essentially meaningless given the earnings volatility.
Relative to the broader healthcare distribution sector, Cencora's forward PE of 15.59x is in line with or slightly below the typical 15-20x range for large-cap distributors, while its PS ratio of 0.19x and EV/Sales of 0.213x are extremely low, reflecting the high-revenue, low-margin nature of the business. The PEG ratio of 7.05 is elevated and suggests the stock is not cheap relative to its expected growth rate, and the price-to-book of 40.17x is distorted by the tiny equity base rather than signaling a genuine premium. On EV/EBITDA of 17.91x, the stock looks fairly valued to slightly rich for a distributor, meaning the discount on sales-based metrics is offset by a premium on earnings-based ones.
Historically, Cencora's PE has ranged from roughly 9.3x (Q2 2026) to over 3,000x (Q4 2024, distorted by near-zero earnings), with more normal readings in the 15-30x band across 2023-2025; the current trailing PE of 38.97x is above that normal band, but the forward PE of 15.59x is near the low end. The PS ratio of 0.19x is near the low end of its historical range of roughly 0.42x to 0.78x, suggesting the market is pricing in either margin deterioration or a permanent de-rating. The dividend yield of 0.72% and payout ratio of 28.1% are modest and sustainable, providing a small valuation floor, but the stock is not priced for aggressive growth at these levels.
PE
39.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple
Investment Risk Disclosure
Cencora's financial risk profile is dominated by its highly leveraged balance sheet and working-capital-intensive model. Debt-to-equity stands at 7.13x, the current ratio is 0.90 (below 1.0), and free cash flow was negative $2.42 billion in Q1 2026 before recovering to $1.17 billion in Q2 2026. Interest coverage of 8.7x provides adequate but not generous cushion, and with net margins at just 2.09% and gross margins at 4.24%, even a modest compression in drug pricing or a shift in payer mix could meaningfully impair earnings. The company's ROE of 103.06% is an artifact of a tiny equity base (equity multiplier of 24.0x) rather than genuine capital efficiency, and the ROA of 3.56% underscores how little profit the asset base generates.
Market and competitive risks center on valuation compression and sector rotation. COR trades at a trailing PE of 38.97x, above its normal 15-30x historical band, though the forward PE of 15.59x is near the low end; the gap reflects uncertainty about the sustainability of the earnings recovery. The PEG ratio of 7.05 and price-to-book of 40.17x suggest the market is paying a premium on earnings-based metrics even as sales-based metrics (PS of 0.19x, EV/Sales of 0.213x) look cheap. With a beta of 0.574, the stock is defensively positioned but will likely lag in strong risk-on rallies, and its 22.99% six-month relative underperformance versus SPY highlights persistent rotation out of healthcare distribution. Competitive pressure from McKesson and Cardinal Health, both of which are also expanding in specialty and generics, could cap Cencora's margin expansion.
The worst-case scenario would involve a combination of specialty margin reversal, continued revenue deceleration below 3%, and a credit-market tightening that raises refinancing costs on the leveraged balance sheet. In that scenario, the stock could retest its 52-week low of $244.82, representing a 20.7% decline from the current price of $308.78, or fall to the analyst low target of $330.00 (which is above current, so the true downside is the 52-week low). A more severe outcome, consistent with the historical max drawdown of -32.56%, would imply a price near $208, a 32.6% loss. The May 6 gap-down low of $252.74 serves as the first major support shelf; a breakdown below that level would likely accelerate selling toward the low $240s.
FAQ
The most severe risk is financial: debt-to-equity of 7.13x and a current ratio of 0.90 mean the company is highly leveraged and dependent on continued cash generation to service obligations. Second is margin risk: gross margins are only 4.24%, so even a small compression in drug pricing or a shift in payer mix could significantly impair earnings. Third is competitive risk: McKesson and Cardinal Health are also expanding in specialty and generics, which could cap Cencora's margin expansion and market share gains. Fourth is macro/valuation risk: with a beta of 0.574, the stock is defensive but has underperformed SPY by 22.99% over six months, and a rotation out of healthcare distribution could keep the shares range-bound. Ranked by severity: financial leverage, margin compression, competitive pressure, and sector rotation.
The 12-month forecast has three scenarios: a base case (55% probability) targeting $340-$380, a bull case (25% probability) targeting $400-$430, and a bear case (20% probability) targeting $245-$280. The base case assumes revenue growth of 3-4%, stable gross margins around 4.2-4.4%, and the stock converging toward the analyst average target of $369.31. The bull case requires specialty margins to expand above 4.5% and revenue growth to reaccelerate above 5%, while the bear case assumes revenue growth falls below 2% and the stock retests its 52-week low of $244.82. The most likely scenario is the base case, with the key assumption being that the specialty mix shift continues to improve margins modestly without a dramatic acceleration.
COR appears undervalued on sales-based metrics but fairly valued on earnings-based ones. The PS ratio of 0.19x and EV/Sales of 0.213x are near the low end of the historical range of 0.42x-0.78x, suggesting the market is pricing in permanent margin deterioration. However, the EV/EBITDA of 17.91x is in line with or slightly above the typical 15-20x range for large-cap distributors, and the PEG ratio of 7.05 is elevated. The forward PE of 15.59x is undemanding relative to the trailing PE of 38.97x, implying the market expects a dramatic earnings recovery that consensus EPS of $31.74 already reflects. Overall, the valuation implies the market expects modest growth with stable margins, and any upside surprise on specialty margins could drive multiple expansion.
From a risk/reward perspective, COR offers a favorable setup with 19.6% upside to the analyst average target of $369.31 and a forward PE of 15.59x that is near the low end of its historical range. The bull case is supported by tangible margin expansion (gross margin up to 4.24% in Q2 2026) and a unanimous buy consensus from 13 analysts. However, the biggest downside risk is a retest of the 52-week low of $244.82, which would represent a 20.7% loss from the current price of $308.78. This makes COR a good buy for value-oriented investors with a medium-to-long-term horizon who can tolerate near-term volatility, but less suitable for short-term traders given the stock's 22.99% six-month relative underperformance versus SPY.
COR is better suited for long-term investment than short-term trading. The stock has a beta of 0.574, meaning it is roughly 43% less volatile than the market, which limits short-term trading opportunities. It pays a modest dividend (0.72% yield) with a sustainable 28.1% payout ratio, appealing to income-oriented long-term holders. The company is in a mature growth stage with revenue growing at 3.85% YoY, and earnings visibility is moderate given the recent volatility (Q4 2025 net loss of $339.7 million versus Q2 2026 net income of $1.64 billion). A suggested minimum holding period is 12-18 months to allow the specialty margin story to fully play out and for the stock to converge toward analyst targets. Short-term traders should note the stock's 22.99% six-month relative underperformance versus SPY and the lack of a clear technical trend.